These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 12047043

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
    Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K.
    J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
    Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H.
    J Cardiovasc Pharmacol; 2006 Oct; 48(4):135-42. PubMed ID: 17086090
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
    Smith DH.
    Am J Cardiovasc Drugs; 2007 Oct; 7(5):347-56. PubMed ID: 17953473
    [Abstract] [Full Text] [Related]

  • 13. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.
    Brunner HR, Nussberger J.
    J Hypertens Suppl; 2001 Jun; 19(1):S15-20. PubMed ID: 11451210
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF, Franks AM.
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Olmesartan medoxomil: an angiotensin II-receptor blocker.
    Brousil JA, Burke JM.
    Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
    [Abstract] [Full Text] [Related]

  • 20. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
    Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y.
    Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.